JP6964351B2 - 新規ｔ細胞受容体およびそれを用いた免疫療法 - Google Patents

新規ｔ細胞受容体およびそれを用いた免疫療法 Download PDF

Info

Publication number
JP6964351B2
JP6964351B2 JP2019508259A JP2019508259A JP6964351B2 JP 6964351 B2 JP6964351 B2 JP 6964351B2 JP 2019508259 A JP2019508259 A JP 2019508259A JP 2019508259 A JP2019508259 A JP 2019508259A JP 6964351 B2 JP6964351 B2 JP 6964351B2
Authority
JP
Japan
Prior art keywords
cancer
seq
amino acid
antigen recognition
tcr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019508259A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528061A (ja
JP2019528061A5 (enExample
Inventor
アルテン，レオニー
マウラー，ドミニク
ウォルター，ステファン
バンク，ゼバスティアン
Original Assignee
イマティクス バイオテクノロジーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60419980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6964351(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イマティクス バイオテクノロジーズ ゲーエムベーハー filed Critical イマティクス バイオテクノロジーズ ゲーエムベーハー
Publication of JP2019528061A publication Critical patent/JP2019528061A/ja
Publication of JP2019528061A5 publication Critical patent/JP2019528061A5/ja
Priority to JP2021128303A priority Critical patent/JP2021184729A/ja
Application granted granted Critical
Publication of JP6964351B2 publication Critical patent/JP6964351B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019508259A 2016-08-17 2017-07-04 新規ｔ細胞受容体およびそれを用いた免疫療法 Expired - Fee Related JP6964351B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021128303A JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662376059P 2016-08-17 2016-08-17
DE102016115246.3 2016-08-17
DE102016115246.3A DE102016115246C5 (de) 2016-08-17 2016-08-17 Neue t-zellrezeptoren und deren verwendung in immuntherapie
US62/376,059 2016-08-17
US201662376632P 2016-08-18 2016-08-18
US62/376,632 2016-08-18
PCT/EP2017/066630 WO2018033291A1 (en) 2016-08-17 2017-07-04 T cell receptors and immune therapy using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128303A Division JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Publications (3)

Publication Number Publication Date
JP2019528061A JP2019528061A (ja) 2019-10-10
JP2019528061A5 JP2019528061A5 (enExample) 2020-02-20
JP6964351B2 true JP6964351B2 (ja) 2021-11-10

Family

ID=60419980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508259A Expired - Fee Related JP6964351B2 (ja) 2016-08-17 2017-07-04 新規ｔ細胞受容体およびそれを用いた免疫療法
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021128303A Pending JP2021184729A (ja) 2016-08-17 2021-08-04 新規ｔ細胞受容体およびそれを用いた免疫療法

Country Status (18)

Country Link
US (2) US10550182B2 (enExample)
EP (1) EP3500593B1 (enExample)
JP (2) JP6964351B2 (enExample)
CN (1) CN109563149A (enExample)
AU (2) AU2017312361B2 (enExample)
BR (1) BR112019001922A2 (enExample)
CA (1) CA3031995A1 (enExample)
CR (1) CR20190095A (enExample)
DE (1) DE102016115246C5 (enExample)
DK (1) DK3500593T3 (enExample)
LT (1) LT3500593T (enExample)
MA (1) MA45976B1 (enExample)
MX (1) MX395287B (enExample)
PE (1) PE20190477A1 (enExample)
RS (1) RS62498B1 (enExample)
SG (1) SG11201900955VA (enExample)
TW (1) TWI775768B (enExample)
WO (1) WO2018033291A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201423361D0 (en) * 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
ZA201900664B (en) * 2016-08-17 2021-09-29 Paul Ehrlich Strasse 15 Tuebingen 72076 Germany T cell receptors and immune therapy using the same
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
CA3070468A1 (en) 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
WO2019086665A1 (en) 2017-11-06 2019-05-09 Immatics Biotechnologies Gmbh Novel engineered t cell receptors and immune therapy using the same
DE102017125888A1 (de) 2017-11-06 2019-05-23 Immatics Biotechnologies Gmbh Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
BR112020025589A2 (pt) 2018-06-19 2021-03-23 Dsm Ip Assets B.V. variantes de enzima lipolítica
WO2020154275A1 (en) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
AU2021238582A1 (en) * 2020-03-16 2022-09-22 Biontech Cell & Gene Therapies Gmbh Antigen-specific T cell receptors and T cell epitopes
WO2021252517A1 (en) * 2020-06-09 2021-12-16 Board Of Regents, The University Of Texas System Engineered t cell receptors and methods of use
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
EP4392441A1 (en) 2021-08-24 2024-07-03 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
CN117986350B (zh) * 2023-02-23 2024-08-16 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
WO2026046995A1 (en) * 2024-08-28 2026-03-05 Pairx Bio Pte. Ltd T cell receptors and uses thereof
CN120718134B (zh) * 2025-08-25 2025-12-26 北京立康生命科技有限公司 靶向col6a3肽的t细胞受体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
WO2006023382A2 (en) * 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagen vi and cancer
EP1762575A1 (en) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
US8105831B2 (en) * 2007-03-09 2012-01-31 University Of Washington Parvoviral production of HLA homozygous cells
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
US9228007B1 (en) * 2010-03-11 2016-01-05 The Regents Of The University Of California Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CN110511960B (zh) * 2013-07-15 2023-05-23 美国卫生和人力服务部 抗人乳头瘤病毒16 e6 t细胞受体
US10738278B2 (en) * 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
RU2739500C2 (ru) * 2014-11-05 2020-12-25 Дженентек, Инк. Способы получения двуцепочечных белков в бактериях

Also Published As

Publication number Publication date
WO2018033291A1 (en) 2018-02-22
TW201806973A (zh) 2018-03-01
AU2017312361A1 (en) 2019-02-28
JP2021184729A (ja) 2021-12-09
AU2017312361B2 (en) 2020-12-10
RS62498B1 (sr) 2021-11-30
SG11201900955VA (en) 2019-03-28
JP2019528061A (ja) 2019-10-10
CN109563149A (zh) 2019-04-02
PE20190477A1 (es) 2019-04-04
US10550182B2 (en) 2020-02-04
MA45976A (fr) 2021-05-19
US20180319884A1 (en) 2018-11-08
US20180051080A1 (en) 2018-02-22
DK3500593T3 (da) 2021-11-01
US10526407B2 (en) 2020-01-07
EP3500593B1 (en) 2021-08-25
MX395287B (es) 2025-03-25
CA3031995A1 (en) 2018-02-22
DE102016115246B3 (de) 2017-12-14
MA45976B1 (fr) 2021-09-30
MX2019001769A (es) 2019-07-08
EP3500593A1 (en) 2019-06-26
BR112019001922A2 (pt) 2019-07-09
AU2021201518A1 (en) 2021-04-01
DE102016115246C5 (de) 2018-12-20
CR20190095A (es) 2019-06-13
TWI775768B (zh) 2022-09-01
LT3500593T (lt) 2021-11-25

Similar Documents

Publication Publication Date Title
JP2021184729A (ja) 新規ｔ細胞受容体およびそれを用いた免疫療法
US10725044B2 (en) T cell receptors and immune therapy using the same
EP3600409B1 (en) T cell receptors and immune therapy using the same against prame positive cancers
TWI735765B (zh) T細胞受體及其針對prame陽性癌症的免疫治療
US11939376B2 (en) T cell receptors and immune therapy using the same
TWI736719B (zh) 新型t 細胞受體及其免疫治療應用
JP2020529830A (ja) 新規ｔ細胞受容体およびそれを用いた免疫療法
TWI790162B (zh) 新穎t細胞受器及使用其之免疫治療
JP2021501589A (ja) 新規操作ｔ細胞受容体およびそれを使用した免疫療法
HK40071461A (en) T cell receptors and immune therapy using the same
HK40010473B (en) T cell receptors and immune therapy using the same
HK40020731A (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40020731B (en) T cell receptors and immune therapy using the same against prame positive cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210325

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210804

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210818

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210823

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210916

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211012

R150 Certificate of patent or registration of utility model

Ref document number: 6964351

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees